Abstract
A series of new tetrahydroquinolines with different substituents at C-2 and C-4 positions in addition to several tetrahydropyrimidoquinolin-4-amines and tetrahydropyrimidoquinoline-2,4-diamines were synthesized. The in vitro anticancer activity of all newly synthesized compounds was tested against human colon carcinoma (HCT116) and human breast adenocarcinoma (MCF7) cell lines. Seven compounds 1a, 5a, 5b, 6a, 6b, 7a and 7b showed potent anticancer activity against both HCT116 and MCF7 cell lines with IC50 between 16.33 and 34.28 µM. All these compounds were more potent than imatinib (IC50 = 34.40 µM) and tamoxifen (IC50 = 34.30 µM). Compound 7b was the most active against HCT116 cell line with 2.1-fold more potent antitumor activity than imatinib. Also, compounds 1a, 5b and 6a exhibited the highest anticancer activity against MCF7 cell line, having two- to 1.79-fold more potent anticancer activity than tamoxifen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
